EP/CE联合与不联合紫杉醇方案治疗复合性小细胞肺癌的临床分析

Clinical Analysis of EP/CE Combined With or Without Paclitaxel Regimen in Treatment of Multiple Small Cell Lung Cancer

目的探讨顺铂/卡铂+依托泊苷(EP/CE)联合与不联合紫杉醇方案治疗复合性小细胞肺癌的临床疗效。方法随机将64例复合性小细胞肺癌患者分成两组,联合组(n=32)采用顺铂/卡铂+依托泊苷+紫杉醇方案,不联合组(n=32)单纯应用顺铂/卡铂+依托泊苷方案,对比两组疗效。结果联合组治疗有效率、中位生存时间均优于不联合组(P<0.01或P<0.05)。结论 EP/CE联合紫杉醇方案治疗复合性小细胞肺癌的临床疗效更佳。

Objective To investigate the clinical efficacy of cisplatin/carboplatin plus etoposide （ EP/CE ） combined with or without paclitaxel regimen in the treatment of multiple small cell lung cancer. Methods Sixty-four patients with combined small cell lung cancer were randomly divided into two groups. The combination group （ n=32 ） was treated with cisplatin/carboplatin plus etoposide and paclitaxel alone or not （ n=32 ） carboplatin ＋ etoposide regimen, compared the two groups. Results The effective rate and the median survival time of the combination group were better than those of the non-combined group （ P 〈 0.01 or P 〈 0.05 ） . Conclusion EP/CE combined with paclitaxel has a better clinical effect in the treatment of small cell lung cancer.